Prosecution Insights
Last updated: November 12, 2026
Application No. 18/744,538

PROTEIN DEGRADATION COMPOUNDS AND METHODS OF USE

Non-Final OA §112
Filed
Jun 14, 2024
Priority
Jun 30, 2022 — provisional 63/357,054 +1 more
Examiner
WILLIS, DOUGLAS M
Art Unit
1624
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Anhorn Medicines Co. Ltd.
OA Round
1 (Non-Final)
82%
Grant Probability
Favorable
1-2
OA Rounds
99%
With Interview

Examiner Intelligence

Grants 82% — above average
82%
Career Allowance Rate
1504 granted / 1825 resolved
+22.4% vs TC avg
Strong +20% interview lift
Without
With
+19.8%
Interview Lift
resolved cases with interview
Typical timeline
Avg Prosecution
66 currently pending
Career history
1874
Total Applications
across all art units

Office Action

§112
DETAILED ACTION Notice of Pre-AIA or AIA Status The inventor or joint inventor should note that the instant invention, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Status of the Claims Claims 1-20 are pending in the instant invention. Status of Priority This invention is a Continuation (CON) of abandoned US Application No. 18/216,566, filed June 29, 2023, which claims priority under 35 U.S.C. § 119(e) to US Provisional Application No. 63/357,054, filed June 30, 2022. Restrictions / Election of Species PNG media_image1.png 254 353 media_image1.png Greyscale PNG media_image2.png 212 362 media_image2.png Greyscale The inventor’s or joint inventor’s provisional election of the following, with traverse, in the reply filed on September 22, 2026, is acknowledged: a) Group I - claims 1-20; and b) substituted piperidine-2,6-dione represented by the instantly recited generic formula - p. 85, CLM of Compound 12, shown to the right below, and hereafter referred to as 3-{4-ethyl-1,3-dioxo-1H,2H,3H,4H-pyrrolo[3,4-b]-indol-2-yl}piperidine-2,6-dione, where each PNG media_image3.png 200 400 media_image3.png Greyscale is a double bond; Q1 = -NRC2-, wherein RC2 = -CH2CH3; Q2 = C; Q3 = CH; Q4 = CH; Q5 = CH; Q6 = CH; Q7 = C; W1 = C; W2 = C; K = -H; G = -H; and n = 0. Claims 1-10 read on the elected species. Affirmation of this election must be made by the inventor or joint inventor in replying to this Office action. Similarly, the inventor or joint inventor should further note that since supposed errors in the restriction requirement were not distinctly and specifically pointed out, the election has been treated as an election, without traverse. See MPEP § 818.03(a). Likewise, the inventor or joint inventor should further note that the requirement is still deemed proper and is therefore made FINAL. Moreover, the inventor or joint inventor should further note that the elected species, shown to the right above, was found to be free of the prior art. Thus, the examiner has expanded the forthcoming prosecution to include all claims relevant to the genus of Group I, for a first Office action and prosecution on the merits. Thus, a first Office action and prosecution on the merits of claims 1-20 is contained within. Specification Objection - Disclosure The inventor or joint inventor is advised to format the specification according to 37 CFR 1.77(c). Revisions should particularly address bold-type, underline, and/or upper case formatting. Appropriate correction may be required. Specification Objection - Title The inventor or joint inventor is reminded of the proper content of the title of the invention. The title of the invention should be brief, but technically accurate and descriptive and should contain fewer than 500 characters. See 37 CFR 1.72(a) and MPEP § 606. The title of the invention is not technically accurate and descriptive. A new title is required that is clearly indicative of the invention to which the claims are directed. In the revised title, the examiner suggests additionally identifying the substituted piperidine-2,6-diones represented by the instantly recited generic formula. The following title is suggested: SUBSTITUTED PIPERIDINE-2,6-DIONES FOR ANDROGEN RECEPTOR DEGRADATION. Appropriate correction is required. Specification Objection - Abstract The inventor or joint inventor is reminded of the proper content of an abstract of the disclosure. With regard particularly to chemical patents, for compounds or compositions, the general nature of the compound or composition should be given as well as the use thereof, e.g., The compounds are of the class of alkyl benzene sulfonyl ureas, useful as oral anti-diabetics. Exemplification of a species could be illustrative of members of the class. For processes, the reactions, reagents and process conditions should be stated, generally illustrated by a single example, unless variations are necessary. See MPEP § 608.01(b), Section B. The abstract of the disclosure is objected to because it fails to exemplify any members or formulae illustrative of its class. Correction is required. See MPEP § 608.01(b). The examiner suggests incorporating the structure of the instantly recited generic formula into the abstract, to overcome this objection. Claim Objections Claim 1 is objected to because of the following informalities: for clarity, precision and to avoid issues under 35 U.S.C. § 112(a) and/or 35 U.S.C. § 112(b), the existing recitation should be replaced with the following recitation: A compound represented by the following formula: PNG media_image4.png 261 447 media_image4.png Greyscale or a pharmaceutically acceptable salt or stereoisomer thereof, wherein: each ----- independently represents a single bond or a double bond; Q1 is -NH-, -NRC2-, -O-, or -S-; Q2 is C; Q3 is C, CH, or CRC2; Q4 is C, CH, or CRC2; Q5 is C, CH, or CRC2; Q6 is C, CH, or CRC2; Q7 is C; W1 is C; W2 is C; K is H, alkyl, or cycloalkyl, wherein the alkyl or cycloalkyl is optionally substituted with one or more independently selected RC2 substituents; G is H, CH2OH, CH2OCH2CH2Si(CH3)3, RC3OC(O)NRC4RC5, RC3OC(O)ORC4, or OH; RC3 is alkylene, wherein the alkylene is optionally substituted with one or more substituents independently selected from the group consisting of halo, NRC4RC5, OH, O(alkyl), OCH2CH2Si(CH3)3, cycloalkyl, heterocyclyl, aryl, and heteroaryl; each RC1 is independently alkyl, alkyl(aryl), O(alkyl), or aryl, wherein each alkyl and aryl is optionally and independently substituted with one or more independently selected RC2 substituents; n is 0, 1, 2, 3, or 4; each RC2 is independently halo, alkyl, CH2OH, CH2OCH2CH2Si(CH3)3, CH2(cycloalkyl), CH2(heterocycyl), CH2(aryl), CH2(heteroaryl), NRC4RC5, O(alkyl), cycloalkyl, heterocyclyl, aryl, or heteroaryl; wherein each alkyl is optionally and independently substituted with one or more substituents independently selected from the group consisting of halo, NRC4RC5, OH, O(alkyl), OCH2CH2Si(CH3)3, cycloalkyl, heterocyclyl, aryl, and heteroaryl; and wherein each cycloalkyl, heterocyclyl, aryl, and heteroaryl is optionally and independently substituted with one or more substituents independently selected from the group consisting of halo, alkyl, CH2OH, CH2OCH2CH2Si(CH3)3, CH2(cycloalkyl), CH2(heterocycyl), CH2(aryl), CH2(heteroaryl), NRC4RC5, O(alkyl), cycloalkyl, heterocyclyl, aryl, and heteroaryl; each RC4 is independently alkyl, cycloalkyl, heterocyclyl, aryl, or heteroaryl; wherein each alkyl is optionally and independently substituted with one or more substituents independently selected from the group consisting of halo, N(alkyl)(alkyl), N(alkyl)(cycloalkyl), N(alkyl)(heterocyclyl), N(alkyl)(aryl), N(alkyl)(heteroaryl), N(cycloalkyl)(cycloalkyl), N(cycloalkyl)(heterocyclyl), N(cycloalkyl)(aryl), N(cycloalkyl)(heteroaryl), N(heterocyclyl)(heterocyclyl), N(heterocyclyl)(aryl), N(heterocyclyl)(heteroaryl), N(aryl)(aryl), N(heteroaryl)(heteroaryl), OH, O(alkyl), OCH2CH2Si(CH3)3, cycloalkyl, heterocyclyl, aryl, and heteroaryl; and wherein each cycloalkyl, heterocyclyl, aryl, and heteroaryl is optionally and independently substituted with one or more substituents independently selected from the group consisting of halo, alkyl, CH2OH, CH2OCH2CH2Si(CH3)3, CH2(cycloalkyl), CH2(heterocycyl), CH2(aryl), CH2(heteroaryl), N(alkyl)(alkyl), N(alkyl)(cycloalkyl), N(alkyl)(heterocyclyl), N(alkyl)(aryl), N(alkyl)(heteroaryl), N(cycloalkyl)(cycloalkyl), N(cycloalkyl)(heterocyclyl), N(cycloalkyl)(aryl), N(cycloalkyl)(heteroaryl), N(heterocyclyl)(heterocyclyl), N(heterocyclyl)(aryl), N(heterocyclyl)(heteroaryl), N(aryl)(aryl), N(heteroaryl)(heteroaryl), O(alkyl), cycloalkyl, heterocyclyl, aryl, and heteroaryl; and each RC5 is independently alkyl, cycloalkyl, heterocyclyl, aryl, or heteroaryl; wherein each alkyl is optionally and independently substituted with one or more substituents independently selected from the group consisting of halo, N(alkyl)(alkyl), N(alkyl)(cycloalkyl), N(alkyl)(heterocyclyl), N(alkyl)(aryl), N(alkyl)(heteroaryl), N(cycloalkyl)(cycloalkyl), N(cycloalkyl)(heterocyclyl), N(cycloalkyl)(aryl), N(cycloalkyl)(heteroaryl), N(heterocyclyl)(heterocyclyl), N(heterocyclyl)(aryl), N(heterocyclyl)(heteroaryl), N(aryl)(aryl), N(heteroaryl)(heteroaryl), OH, O(alkyl), OCH2CH2Si(CH3)3, cycloalkyl, heterocyclyl, aryl, and heteroaryl; and wherein each cycloalkyl, heterocyclyl, aryl, and heteroaryl is optionally and independently substituted with one or more substituents independently selected from the group consisting of halo, alkyl, CH2OH, CH2OCH2CH2Si(CH3)3, CH2(cycloalkyl), CH2(heterocycyl), CH2(aryl), CH2(heteroaryl), N(alkyl)(alkyl), N(alkyl)(cycloalkyl), N(alkyl)(heterocyclyl), N(alkyl)(aryl), N(alkyl)(heteroaryl), N(cycloalkyl)(cycloalkyl), N(cycloalkyl)(heterocyclyl), N(cycloalkyl)(aryl), N(cycloalkyl)(heteroaryl), N(heterocyclyl)(heterocyclyl), N(heterocyclyl)(aryl), N(heterocyclyl)(heteroaryl), N(aryl)(aryl), N(heteroaryl)(heteroaryl), O(alkyl), cycloalkyl, heterocyclyl, aryl, and heteroaryl. Appropriate correction is required. See MPEP § 2173.02. Claim 2 is objected to because of the following informalities: for clarity, precision and to avoid issues under 35 U.S.C. § 112(b) and/or 35 U.S.C. § 112(d), the existing recitation should be replaced with the following recitation: The compound of claim 1, or a pharmaceutically acceptable salt or stereoisomer thereof, wherein: each RC2 is independently C1-6 alkyl or C3-6 cycloalkyl; wherein each C1-6 alkyl is optionally and independently substituted with one or more independently selected halo substituents; and wherein each C3-6 cycloalkyl is optionally and independently substituted with one or more independently selected halo substituents. Appropriate correction is required. See MPEP § 2173.02. Claim 3 is objected to because of the following informalities: for clarity, precision and to avoid issues under 35 U.S.C. § 112(b) and/or 35 U.S.C. § 112(d), the existing recitation should be replaced with the following recitation: The compound of claim 2, or a pharmaceutically acceptable salt or stereoisomer thereof, wherein each RC2 is independently C1-6 alkyl. Appropriate correction is required. See MPEP § 2173.02. Claim 4 is objected to because of the following informalities: for clarity, precision and to avoid issues under 35 U.S.C. § 112(b) and/or 35 U.S.C. § 112(d), the existing recitation should be replaced with the following recitation: The compound of claim 2, or a pharmaceutically acceptable salt or stereoisomer thereof, wherein each RC2 is independently C1-4 alkyl. Appropriate correction is required. See MPEP § 2173.02. Claim 5 is objected to because of the following informalities: for clarity, precision and to avoid issues under 35 U.S.C. § 112(b) and/or 35 U.S.C. § 112(d), the existing recitation should be replaced with the following recitation: The compound of claim 2, or a pharmaceutically acceptable salt or stereoisomer thereof, wherein each RC2 is independently CH3 or CH2CH3. Appropriate correction is required. See MPEP § 2173.02. Claim 7 is objected to because of the following informalities: for clarity, precision and to avoid issues under 35 U.S.C. § 112(a), 35 U.S.C. § 112(b) and/or 35 U.S.C. § 112(d), the existing recitation should be replaced with the following recitation: The compound of claim 1, or a pharmaceutically acceptable salt or stereoisomer thereof, wherein each ----- independently represents a double bond. Appropriate correction is required. See MPEP § 2173.02. Claim 8 is objected to because of the following informalities: for clarity, precision and to avoid issues under 35 U.S.C. § 112(a), 35 U.S.C. § 112(b) and/or 35 U.S.C. § 112(d), the existing recitation should be replaced with the following recitation: The compound of claim 1, or a pharmaceutically acceptable salt or stereoisomer thereof, wherein: each ----- independently represents a double bond; Q2 is C; Q3 is CH or CRC2; Q4 is CH or CRC2; Q5 is CH or CRC2; Q6 is CH or CRC2; and Q7 is C; with the proviso that at least one of Q3, Q4, Q5, and Q6 is CR2. Appropriate correction is required. See MPEP § 2173.02. Claim 9 is objected to because of the following informalities: for clarity, precision and to avoid issues under 35 U.S.C. § 112(a), 35 U.S.C. § 112(b) and/or 35 U.S.C. § 112(d), the existing recitation should be replaced with the following recitation: The compound of claim 1, or a pharmaceutically acceptable salt or stereoisomer thereof, wherein: each ----- independently represents a double bond; Q2 is C; Q3 is CH; Q4 is CH; Q5 is CH; Q6 is CH; and Q7 is C. Appropriate correction is required. See MPEP § 2173.02. Claim 10 is objected to because of the following informalities: for clarity, precision and to avoid issues under 35 U.S.C. § 112(b) and/or 35 U.S.C. § 112(d), the existing recitation should be replaced with the following recitation: The compound of claim 1, or a pharmaceutically acceptable salt or stereoisomer thereof, wherein n is 0, 1, or 2. Appropriate correction is required. See MPEP § 2173.02. Claim 11 is objected to because of the following informalities: for brevity, clarity, precision and to avoid issues under 35 U.S.C. § 112(b) and/or 35 U.S.C. § 112(d), the existing recitation should be replaced with the following recitation: The compound of claim 1, or a pharmaceutically acceptable salt or stereoisomer thereof, wherein RC3 is alkylene. Appropriate correction is required. See MPEP § 2173.02. Claim 12 is objected to because of the following informalities: for clarity, precision and to avoid issues under 35 U.S.C. § 112(b) and/or 35 U.S.C. § 112(d), the existing recitation should be replaced with the following recitation: The compound of claim 1, or a pharmaceutically acceptable salt or stereoisomer thereof, wherein RC3 is C1-6 alkylene. Appropriate correction is required. See MPEP § 2173.02. Claim 13 is objected to because of the following informalities: for clarity, precision and to avoid issues under 35 U.S.C. § 112(b) and/or 35 U.S.C. § 112(d), the existing recitation should be replaced with the following recitation: The compound of claim 1, or a pharmaceutically acceptable salt or stereoisomer thereof, wherein RC3 is C1-4 alkylene. Appropriate correction is required. See MPEP § 2173.02. Claim 14 is objected to because of the following informalities: for clarity, precision and to avoid issues under 35 U.S.C. § 112(b) and/or 35 U.S.C. § 112(d), the existing recitation should be replaced with the following recitation: The compound of claim 1, or a pharmaceutically acceptable salt or stereoisomer thereof, wherein RC3 is -CH2-, -CH(CH3)-, or -CH2CH2-. Appropriate correction is required. See MPEP § 2173.02. Claim 15 is objected to because of the following informalities: for clarity, precision and to avoid issues under 35 U.S.C. § 112(b) and/or 35 U.S.C. § 112(d), the existing recitation should be replaced with the following recitation: The compound of claim 1, or a pharmaceutically acceptable salt or stereoisomer thereof, wherein RC3 is -CH2-. Appropriate correction is required. See MPEP § 2173.02. Claim 16 is objected to because of the following informalities: for clarity, precision and to avoid issues under 35 U.S.C. § 112(b) and/or 35 U.S.C. § 112(d), the existing recitation should be replaced with the following recitation: The compound of claim 1, or a pharmaceutically acceptable salt or stereoisomer thereof, wherein each RC4 is independently alkyl; wherein each alkyl is optionally and independently substituted with one or more substituents independently selected from the group consisting of halo, N(alkyl)(alkyl), N(alkyl)(cycloalkyl), N(alkyl)(heterocyclyl), N(alkyl)(aryl), N(alkyl)(heteroaryl), N(cycloalkyl)(cycloalkyl), N(cycloalkyl)(heterocyclyl), N(cycloalkyl)(aryl), N(cycloalkyl)(heteroaryl), N(heterocyclyl)(heterocyclyl), N(heterocyclyl)(aryl), N(heterocyclyl)(heteroaryl), N(aryl)(aryl), N(heteroaryl)(heteroaryl), OH, O(alkyl), OCH2CH2Si(CH3)3, cycloalkyl, heterocyclyl, aryl, and heteroaryl. Appropriate correction is required. See MPEP § 2173.02. Claim 17 is objected to because of the following informalities: for clarity, precision and to avoid issues under 35 U.S.C. § 112(b) and/or 35 U.S.C. § 112(d), the existing recitation should be replaced with the following recitation: The compound of claim 1, or a pharmaceutically acceptable salt or stereoisomer thereof, wherein each RC4 is independently alkyl. Appropriate correction is required. See MPEP § 2173.02. Claim 18 is objected to because of the following informalities: for clarity, precision and to avoid issues under 35 U.S.C. § 112(b) and/or 35 U.S.C. § 112(d), the existing recitation should be replaced with the following recitation: The compound of claim 1, or a pharmaceutically acceptable salt or stereoisomer thereof, wherein each RC4 is independently C1-6 alkyl. Appropriate correction is required. See MPEP § 2173.02. Claim 19 is objected to because of the following informalities: for clarity, precision and to avoid issues under 35 U.S.C. § 112(b) and/or 35 U.S.C. § 112(d), the existing recitation should be replaced with the following recitation: The compound of claim 1, or a pharmaceutically acceptable salt or stereoisomer thereof, wherein each RC4 is independently C1-4 alkyl. Appropriate correction is required. See MPEP § 2173.02. Claim 20 is objected to because of the following informalities: for clarity, precision and to avoid issues under 35 U.S.C. § 112(b) and/or 35 U.S.C. § 112(d), the existing recitation should be replaced with the following recitation: The compound of claim 1, or a pharmaceutically acceptable salt or stereoisomer thereof, wherein each RC4 is independently CH3 or CH2CH3. Appropriate correction is required. See MPEP § 2173.02. Claim Rejections - 35 U.S.C. § 112(b) The following is a quotation of the second paragraph of 35 U.S.C. § 112: (b) CONCLUSION. The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the inventor or joint inventor regards as the invention. Claim 2 is rejected under 35 U.S.C. § 112(b) as being indefinite for failing to set forth the subject matter which the inventor or joint inventor regards as the invention. The inventor or joint inventor should note that claim 2 recites the limitation, C1-6 cycloalkyl, with respect to RC2, where the limitation is implausible, resulting in an incomplete valence. Claims are unduly speculative where they define only a portion of a substituted piperidine-2,6-dione represented by the instantly recited generic formula. Consequently, since incomplete valences are not permitted in the structure of the substituted piperidine-2,6-diones represented by the instantly recited generic formula, an essential portion of the substituted piperidine-2,6-diones represented by the instantly recited generic formula is indefinite and one of ordinary skill in the art would not be reasonably apprised of the metes and bounds of the substituted piperidine-2,6-diones represented by the instantly recited generic formula. {See Ex parte Pedlow and Miner, 90 USPQ 395 (Bd. Pat. App. & Int. 1951)}. The examiner suggests amending the claim, particularly as stated in the section above entitled Claim Objections, to overcome this rejection. Claim Rejections - 35 U.S.C. § 112(d) The following is a quotation of the fourth paragraph of 35 U.S.C. § 112: (d) REFERENCE IN DEPENDENT FORMS. Subject to subsection (e), a claim in dependent form shall contain a reference to a claim previously set forth and then specify a further limitation of the subject matter claimed. A claim in dependent form shall be construed to incorporate by reference all the limitations of the claim to which it refers. Claim 6 is rejected under 35 U.S.C. § 112(d) as being of improper dependent form for failing to further limit the subject matter of the claim upon which it depends, or for failing to include all the limitations of the claim upon which it depends. The inventor or joint inventor should note that claim 6 recites the limitation, The… compound of claim 1, wherein W1 and W2 are connected together through a double bond, in lines 1-2 of the claim. According to claim 1, since W1 is C and W2 is C, W1 and W2 are connected together through a double bond, with respect to the substituted piperidine-2,6-diones represented by the instantly recited generic formula. Consequently, since The… compound of claim 1, wherein W1 and W2 are connected together through a double bond, fails to specify a further limitation to the substituted piperidine-2,6-diones represented by the generic formula, as recited in claim 1, and/or fails to include all the limitations of the substituted piperidine-2,6-diones represented by the generic formula, as recited in claim 1, the instant dependent claim is rendered improperly dependent under 35 U.S.C. § 112(d). Similarly, the inventor or joint inventor should further note that the U.S. Court of Appeals for the Federal Circuit indicated that although the requirements of 35 U.S.C. § 112(d) are related to matters of form, non-compliance with 35 U.S.C. § 112(d) renders the claim unpatentable just as non-compliance with other subsections of 35 U.S.C. § 112 would. {See Pfizer, Inc. v. Ranbaxy Labs., Ltd., 457 F.3d 1284, 1291-92 (Fed. Cir. 2006)}. Moreover, the inventor or joint inventor should further note that if a dependent claim does not comply with the requirements of 35 U.S.C. § 112(d) the dependent claim should be rejected under 35 U.S.C. § 112(d) as unpatentable rather than objecting to the claim. {See also MPEP § 608.01(n), Section III, Infringement Test for dependent claims}. The examiner suggests the inventor or joint inventor (1) cancel the dependent claim, (2) amend the dependent claim to place the dependent claim in proper dependent form, (3) rewrite the dependent claim in independent form, or (4) present a sufficient showing that the dependent claim complies with the statutory requirements, to overcome this rejection. Claim 7 is rejected under 35 U.S.C. § 112(d) as being of improper dependent form for failing to further limit the subject matter of the claim upon which it depends, or for failing to include all the limitations of the claim upon which it depends. The inventor or joint inventor should note that claim 7 recites the limitation, The… compound of claim 1, wherein Q2, Q3, Q4, Q5, Q6 and Q7 together form a… heterobenzen ring…, in lines 1-2 of the claim. According to claim 1, since Q2, Q3, Q4, Q5, Q6 and Q7 are independently C, CH, or CRC2, Q2, Q3, Q4, Q5, Q6 and Q7 together may not form a heterobenzen ring, with respect to the substituted piperidine-2,6-diones represented by the instantly recited generic formula. Consequently, since The… compound of claim 1, wherein Q2, Q3, Q4, Q5, Q6 and Q7 together form a… heterobenzen ring…, fails to specify a further limitation to the substituted piperidine-2,6-diones represented by the generic formula, as recited in claim 1, and/or fails to include all the limitations of the substituted piperidine-2,6-diones represented by the generic formula, as recited in claim 1, the instant dependent claim is rendered improperly dependent under 35 U.S.C. § 112(d). Similarly, the inventor or joint inventor should further note that the U.S. Court of Appeals for the Federal Circuit indicated that although the requirements of 35 U.S.C. § 112(d) are related to matters of form, non-compliance with 35 U.S.C. § 112(d) renders the claim unpatentable just as non-compliance with other subsections of 35 U.S.C. § 112 would. {See Pfizer, Inc. v. Ranbaxy Labs., Ltd., 457 F.3d 1284, 1291-92 (Fed. Cir. 2006)}. Moreover, the inventor or joint inventor should further note that if a dependent claim does not comply with the requirements of 35 U.S.C. § 112(d) the dependent claim should be rejected under 35 U.S.C. § 112(d) as unpatentable rather than objecting to the claim. {See also MPEP § 608.01(n), Section III, Infringement Test for dependent claims}. The examiner suggests the inventor or joint inventor (1) cancel the dependent claim, (2) amend the dependent claim to place the dependent claim in proper dependent form, particularly as stated in the section above entitled Claim Objections, (3) rewrite the dependent claim in independent form, or (4) present a sufficient showing that the dependent claim complies with the statutory requirements, to overcome this rejection. Claim 8 is rejected under 35 U.S.C. § 112(d) as being of improper dependent form for failing to further limit the subject matter of the claim upon which it depends, or for failing to include all the limitations of the claim upon which it depends. The inventor or joint inventor should note that claim 8 recites the limitation, The… compound of claim 1, wherein Q2, Q3, Q4, Q5, Q6 and Q7 together form an unsubstitted… hetero-benzen ring…, in lines 1-2 of the claim. According to claim 1, since Q2, Q3, Q4, Q5, Q6 and Q7 are independently C, CH, or CRC2, Q2, Q3, Q4, Q5, Q6 and Q7 together may not form an unsubstituted heterobenzen ring, with respect to the substituted piperidine-2,6-diones represented by the instantly recited generic formula. Consequently, since The… compound of claim 1, wherein Q2, Q3, Q4, Q5, Q6 and Q7 together form an unsubstituted… heterobenzen ring…, fails to specify a further limitation to the substituted piperidine-2,6-diones represented by the generic formula, as recited in claim 1, and/or fails to include all the limitations of the substituted piperidine-2,6-diones represented by the generic formula, as recited in claim 1, the instant dependent claim is rendered improperly dependent under 35 U.S.C. § 112(d). Similarly, the inventor or joint inventor should further note that the U.S. Court of Appeals for the Federal Circuit indicated that although the requirements of 35 U.S.C. § 112(d) are related to matters of form, non-compliance with 35 U.S.C. § 112(d) renders the claim unpatentable just as non-compliance with other subsections of 35 U.S.C. § 112 would. {See Pfizer, Inc. v. Ranbaxy Labs., Ltd., 457 F.3d 1284, 1291-92 (Fed. Cir. 2006)}. Moreover, the inventor or joint inventor should further note that if a dependent claim does not comply with the requirements of 35 U.S.C. § 112(d) the dependent claim should be rejected under 35 U.S.C. § 112(d) as unpatentable rather than objecting to the claim. {See also MPEP § 608.01(n), Section III, Infringement Test for dependent claims}. The examiner suggests the inventor or joint inventor (1) cancel the dependent claim, (2) amend the dependent claim to place the dependent claim in proper dependent form, particularly as stated in the section above entitled Claim Objections, (3) rewrite the dependent claim in independent form, or (4) present a sufficient showing that the dependent claim complies with the statutory requirements, to overcome this rejection. Allowable Subject Matter No claims are allowed. Conclusion Any inquiry concerning this communication or earlier communications from the examiner should be directed to DOUGLAS M. WILLIS, whose telephone number is 571-270-5757. The examiner may normally be reached on Monday thru Thursday from 8:00-6:00 EST. The examiner is also available on alternate Fridays. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Mr. Jeffrey Murray, may be reached on 571-272-9023. The fax phone number for the organization where this invention or proceeding is assigned is 571-273-8300. Information regarding the status of an invention may be obtained from Patent Center. For more information about Patent Center, see https://www.uspto.gov/patents/apply/patent-center. Should you have questions on access to Patent Center, contact the Patent Electronic Business Center (PEBC) at 866-217-9197 (toll-free) or ebc@uspto.gov. /DOUGLAS M WILLIS/ Primary Examiner, Art Unit 1624
Read full office action

Prosecution Timeline

Jun 14, 2024
Application Filed
Oct 26, 2026
Non-Final Rejection mailed — §112 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12788697
TOPICAL AGENTS FOR DERMATOLOGICAL APPLICATIONS
4y 0m to grant Granted Nov 10, 2026
Patent 12778965
COMBINATION CANCER THERAPY WITH PENTAAZA MACROCYCLIC RING COMPLEX AND HORMONE THERAPY AGENT
3y 11m to grant Granted Nov 03, 2026
Patent 12780838
MTORC1 MODULATORS AND USES THEREOF
3y 8m to grant Granted Nov 03, 2026
Patent 12774296
PYRIDINE-2-AMINE DERIVATIVE AND PHARMACEUTICAL COMPOSITION AND USE THEREOF
3y 4m to grant Granted Oct 27, 2026
Patent 12767660
CONDENSED HETEROCYCLIC COMPOUND
4y 0m to grant Granted Oct 20, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

1-2
Expected OA Rounds
82%
Grant Probability
99%
With Interview (+19.8%)
Low
PTA Risk
Based on 1825 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month